Clinical Success of Stage III of Mercado, Bayer Heart Failure Drugs

On November 19, Mercado and partner Bayer announced that vericiguat, a soluble bird nucleotide cyclosarinase (sGC) agonist, had reached a compound level 1 consisting of heart failure hospitalization and cardiovascular death in a phase III clinical trial called VICTORIAThe trial, which recruited 5,050 patients with a left ventricular hemorrhagic hemorrhage disorder (HFrEF) whose symptoms of heart failure was worsening, resulted in Vericiguat having a significantly lower risk of cardiovascular death and hospitalization than placebos in standard therapy backgroundsThe drug also has a phase II clinical phase II clinical in patients with more difficult left ventricular ventricular radiation function to preserve heart failure (HFpEF)the analysis of the drug source
Vericiguat was first discovered by Bayer, which paid $1 billion in 2014 to gain a U.Smarket interest, and today the third phase is in the charge of MercadoVericiguat is a soluble bird nucleotide cyclase (sGC) agonist, which has low levels of cGMP due to insufficient cGMP levels and is associated with heart muscle damageVericiguat can either activate the sGC directly or increase the sensitivity of the sGC to NO, thus increasing the activity of the NO-sGC-cGMP pathwayNO itself is a popular molecule, once developed as one of the gods, but its safety window is limited, poor toleranceTwenty years ago, a combination of a combination of the target ingestion of this pathway, quyssin and nitric acid isonate, was approved for the market, but only for patients of African descent, but also caused considerable ethical debateVericiguat failed in a phase II clinical clinic ending with heart failure labeled NT-pro (bioprecursor of the hormone BNP), but the high-dose group (10 mg) barely achieved statistical lying to the control ratioThe decline in NT-proBNP levels as a substitute for relieving heart failure is not supported by strict data, and a trial called GUIDE-IT used the marker to adjust the drug to improve treatment end-of-life was terminated prematurely because of ineffectivenessThree years ago, Mersadon and Bayer began the VICTORIA trial, in which patients could use up to 10 mg at low dosesheart failure is a major disease, with 60 million patients worldwideIn the United States alone, 1 million people are hospitalized each year for heart failure, and about one-third die within a yearHeart failure is one of the final manifestations of body aging, so aging population is bound to cause the number of heart failure patients to continue to increaseThis is clearly a class of diseases with high heterogeneity, and a single mechanism is unlikely to be effective for most peopleHeart failure is divided into Two categories, HFrEF and HFpEF according to the function of left ventricular radiation, but the pathological basis is very differentHFrEF is relatively easy to control, and the most important recent developments have been the launch of Novartis antihypertensive combination Entresto and the unexpected application of SGLT2 inhibitors in HFrEFBut HFpEF has not had a successful drug in the last 20 years, with potassium diuretic stool studs, saggin analogues Serelaxin, and Entresto all failingdetails of the trial were not released today, and it is unclear exactly how many standard therapies are recently releasedIf most people do not use Entresto, then Vericiguat needs a significant reduction in risk to be commercially competitive, and experts predict that Vericiguat will need to reduce risk by 15-20% on the Background of EntrestoThe high-flying production of Entreso and SGLT2 inhibitors has made it difficult for Vericiguat to become too big a product, with sales now expected to reach $400 million by 2024But if Vericiguat can be successful in HFpEF's VITALITY trial, the commercial future of the product will be greatly improvedthe product started the 5,000-strong, 600-plus-center clinical trial based on weak Phase II data, it took a lot of risks, but even after such a successful gamble, The business prospects for Vericiguat are still not widely viewed, reflecting the difficulty of developing common mass disease drugsIn addition to the high risk, high heterogeneous disease drugs are destined to benefit from a limited number of people, which determines that only long-term large-scale trials can see the differenceThis not only increases research and development costs and shortens product life, but also makes the pharmaceutical industry a topic of criticism for not benefiting most patientsEven then, the drug King Liputto needed 200 people to take a year to avoid a case of heart attack, the drug became to buy insuranceThese factors have forced the pharmaceutical industry to move away from the traditional heavy-duty drug model and tilt toward precision drugs, and Vericiguat may be one of the last nobility.